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Abstract. Background: Lymphangioleiomyomatosis (LAM) is
a progressive, rare interstitial lung disease that almost
exclusively affects women. It is caused by a mutation in one of
the tuberous sclerosis genes, TSC1 or TSC2, and constitutive
activation of the mammalian target of rapamycin (mTOR)
pathway in smooth muscle-like cells (LAM cells). The
heightened proliferation and accumulation of LAM cells leads
to the destruction of lung tissue. Materials and Methods: In the
present study, we developed a cell line (S-LAM1) derived from
a chylous effusion obtained from a patient with sporadic,
pulmonary LAM and evaluated its phenotype using
immunofluorescence, flow cytometry, and an image stream
system. Ultrastructure was assessed using a transmission
electron microscope. To assess the ability of LAM cells to move
and migrate (which is strictly associated with the ability to
metastasize), we carried-out a real-time polymerase chain
reaction (PCR) array analysis of 84 genes involved in cell
motility. In order to evaluate the effect of rapamycin, a natural
inhibitor of mTOR kinase, on S-LAM1 cells, a sulforhodamine B
cell viability assay was performed with different concentrations
of rapamycin. Results and Conclusion: The phenotype of these
cells is consistent with the biology of LAM cells. S-LAM1 cells
present combined smooth muscle, melanocytic, and lymphatic
endothelium lineage, as well as the presence of mesenchymal
differentiation markers. A particular pattern of gene expression,
including high expression of ezrin (EZR), myosin heavy chain
10, non-muscle (MYH10), and myosin light chain kinase
(MYLK) and a greatly decreased expression of supervillin
(SVIL), when compared to controls, indicates a high potential
motility activity, especially of cell spreading. Rapamycin
significantly, although only partially, inhibited S-LAM1 cell
proliferation in vitro, and should, perhaps, be considered in the
future in combination with other agents.
Lymphangioleiomyomatosis (LAM) is a progressive, rare
interstitial lung disease that almost exclusively affects
women. It is caused by a mutation in one of the tuberous
sclerosis genes, TSC1 or TSC2, leading to the constitutive
activation of the mammalian target of rapamycin (mTOR)
pathway and excessive proliferation of smooth muscle-like
cells (LAM cells) (1). LAM may occur in a sporadic form
(mutation of TSC gene in somatic cells), or may be
associated with tuberous sclerosis complex (TSC), an
autosomal-dominant disease characterized by hamartoma
tumor formation in various organs, such as the skin, eyes,
kidneys, lungs, and the central nervous system (2). LAM
occurs in about 3 to 8 out of 1 million women and affects
about 30% of women with TSC (1). 
Intense proliferation and accumulation of LAM cells in the
lungs and around the bronchi, blood, and lymphatic vessels
leads to the destruction of the lung tissue and the formation of
thin-walled cysts (3). LAM cell populations are
heterogeneous and differ in morphology, localization in the
LAM nodule, and marker expression. We can distinguish
smaller, spindle-shaped, smooth muscle-like cells, which are
located mostly in the central part of the LAM nodule, and
larger epithelioid-like cells occurring peripherally (4, 5). The
phenotype of LAM cells combines features of smooth muscle
and melanoma cells. LAM cells express smooth muscle actin
(αSMA), vimentin, and desmin, and are immunoreactive with
human melanoma black 45 (HMB45), PNL2, and antibodies
to CD63 (6). Immunohistochemical reaction with HMB45 has
become a useful diagnostic tool in LAM (7). 
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LAM cells have the ability to be invasive and to
metastasize; their presence has been observed in blood,
urine, bronchoalveolar lavage fluid, and chyle (8-10).
Metastasis and invasiveness is strictly dependent on cancer
cell motility and migration. The mechanisms of cell motility
include specific steps such as cytoskeletal reorganization,
cell polarization, lamellipodial protrusion, adhesion, cell
contractility, and detachment. Each step is regulated by a
specific group of factors. Ras homolog gene family (RHO)
proteins play an important role in these mechanisms.
Moreover, many of the classic growth factors, such as
epidermal growth factor (EGF) and hepatocyte growth factor
(HGF), are known to promote cell migration (11, 12).
Excessive proliferation of LAM cells is caused by the
constitutive activation of the mTOR pathway (1). To date,
rapamycin (Sirolimus), a natural inhibitor of mTOR, seems
to be the most promising therapeutic solution for LAM (13).
Reductions in tumor volume and improvement in lung
function has been reported in patients with LAM following
treatment with rapamycin (14-16).
Sporadic LAM is an extremely rare disease; a useful
experimental model of this disease is therefore necessary for
further studies of its pathomechanisms. However, up-
regulation of the mTOR pathway also occurs in many other
types of neoplasm. The characterization and better
understanding of LAM cell biology may facilitate research
into new therapeutic approaches not only for LAM but also
for other types of cancer. 
In our study, based on this background, we characterized
cells cultured from chylous effusion obtained from a patient
with pulmonary, sporadic LAM. Phenotypic characterization
of the derived S-LAM1 cells was performed using
immunofluorescence, flow cytometry, and an image stream
system. The ultrastructure of these cells was revealed by
transmission electron microscopy (TEM). In order to gain
insight into the cultured cell’s ability to migrate, which is
associated with the ability to metastasize, we performed a
real-time polymerase chain reaction (PCR) array analysis of
84 genes involved in cell motility mechanisms. Finally, we
investigated the influence of rapamycin on S-LAM1 cells
using a sulforhodamine B (SRB) cell viability assay.
Materials and Methods
Cell culture. S-LAM1 cells were cultured from the chylous effusion
obtained from a 42-year-old female patient with sporadic pulmonary
LAM. The case report has previously been presented (16). The cells
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Lonza, Basel, Switzerland), containing 10% fetal bovine serum
(Lonza) and 2 mM L-glutamine, at 37˚C in the presence of 5% CO2.
The cells were used in their fourth to tenth passages in all
experiments. 
Pulmonary artery smooth muscle cells (PASMs) (Lonza) were
grown in smooth muscle growth medium-2 (SmGM-2) (Lonza)
containing 5% fetal bovine serum at 37˚C in the presence of 5%
CO2. The cells were used in the fourth to eighth passages in all
experiments. The study was approved by the Bioethical Committee
of the Wrocław Medical University (approval number KB-
594/2012).
Fluorescence microscopy. S-LAM1 cells grown on glass coverslips
were incubated at 37˚C for 24 hours, and then washed with
phosphate buffered saline (PBS). Cells were fixed in 4%
glutaraldehyde for 10 min and washed with PBS. After washing, the
cells were treated with 0.2% Triton-X and washed in PBS again.
The slides were incubated at 4˚C overnight with primary antibodies:
monoclonal mouse antihuman melanosome (clone HMB-45 at
dilution 1:100; Dako, Glostrup, Denmark), monoclonal mouse
antihuman α-SMA [clone 1A4, ready to use (RTU); Dako],
monoclonal mouse antihuman vimentin (clone V9, RTU; Dako), and
monoclonal mouse antihuman podoplanin (clone D2-40, RTU,
Dako). After washing three times in PBS, the slides were incubated
for 1 h at room temperature in the dark with donkey anti-mouse
secondary antibody conjugated with fluorescein isothiocyanate
(FITC) (Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA, USA), diluted 1:50 in antibody diluent (Dako). After washing,
the slides were covered with Vectashield mounting medium for
fluorescence with 4’,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Inc, Burlingame, CA, USA), and viewed and imaged
with a BX51 fluorescence microscope (Olympus, Tokyo, Japan).
Flow cytometry and image stream system. For flow cytometric
immunophenotyping, a single-cell suspension of S-LAM1 cells [in
PBS with 2% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA,
USA)] was stained with the following monoclonal antibodies
against human antigens: CD45-FITC, hepatocyte growth factor
receptor (c-MET-FITC), CD90-phycoerythrin (CD90-PE), CD105-
PE, CD31-PE, CD29 PE-Cy5 (all antibodies from BD Bioscience,
San Jose, CA, USA), STRO1-Alexa Fluor 647/APC (BioLegend,
San Diego, CA, USA), CD133-allophycocyanin (CD133-APC)
(Miltenyi Biotec, Bergisch Gladbach, Germany), HMB45-FITC
(DAKO), and CD9-APC (BD Bioscience, San Jose, CA, USA).
Cells were incubated with the directly conjugated antibodies for 30
min on ice and were subsequently washed and resuspended in PBS
with 2% FBS for further multicolor analysis in an LSR II flow
cytometer (Becton Dickinson, Franklin Lakes, New Jersey, USA). 
Intracellular proteins, including vimentin and αSMA (DAKO),
were identified in S-LAM1 cells following fixation [with 2%
paraformaldehyde (Sigma, St. Louis, MO, USA) for 20 min at room
temperature] and permabilization [with 0.2% Triton-X solution
(Sigma) for 10 min at room temperature]. The washed cells were
subsequently stained with anti-human vimentin or anti-human
αSMA primary antibodies (mouse polyclonal IgG; Dako) and
immunolabeled with antimouse secondary antibody conjugated with
PE (BioLegend). All antibodies were added in accordance to the
manufacturers’ protocols. The cells were subsequently washed and
resuspended in PBS with 2% FBS for further analysis in an LSR II
flow cytometer (Becton Dickinson).
For immunophenotyping with imaging cytometry, S-LAM1 cells
were stained as described above using the antibodies employed for
classical flow cytometry (listed above). Cells were additionally
stained with 7-aminoactinomycin D (7-AAD; according to the
manufacturers’ protocol) in order to visualize nuclei, and were
subsequently analyzed using ImageStream X system (Amnis Corp.,
Seattle, WA, USA).
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TEM. In order to perform an ultrastructural analysis of the S-LAM1
cells, cells grown in 75 cm2 flasks were trypsinized and fixed with
2.5% (v/v) glutaraldehyde (Merck, Dramstadt, Germany) in 0.1 M
sodium cacodylate (Fluka, St. Gallen, Switzerland) at a pH of 7.4
for 30 min at room temperature. After washing in cacodylate buffer,
the addition of bovine thrombin (Biomed, Lublin, Poland) and
fibrinogen (Fluka) resulted in fibrin clot formation, in which the
cells were entrapped. The samples were then postfixed with 2%
(w/v) OsO4 (Serva, Heidelberg, Germany) in 0.1 M cacodylate
buffer for 1 h at RT, passed through a series of ethanol and acetone
solutions, and finally embedded in Epon 812 (Roth, Karlsruhe,
Germany). Ultrathin sections were prepared, stained with uranyl
acetate/lead citrate (Fluka), and examined with a TEM JEM-1011
(JEOL, Tokyo, Japan).
Human cell motility real-time PCR array. Total RNA was extracted
from six independent samples of S-LAM1 cells and PASMs using
the RNeasy Mini Kit (Qiagen, Hilden, Germany) in line with the
manufacturer’s instructions. The RNA products were quantified by
absorbance at 260 nm with a NanoDrop1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA). RNA quality was
assessed using a bioanalyzer (Agilent, Santa Clara, CA, USA).
First-strand cDNA was synthesized using the RT2 First Strand Kit
(SABiosciences, Frederick, MD, USA). cDNA was subsequently
combined with the RT2qPCR Master Mix, according to the
manufacturer’s instructions, and applied to pathway-specific RT2
Profiler PCR Arrays (SABiosciences, Frederick, MD, USA) for cell
motility. This included a total of 96 genes involved in the movement
of cells, such as growth factors and receptors important for
chemotaxis, genes involved in RHO family signaling and adhesion,
and genes encoding components of various cellular projections and
control genes. A 7500 Real-Time PCR System (Applied Biosystems,
Carlsbad, CA, USA) was used with the following cycle conditions:
one cycle at 95 ˚C for 10 min, 40 cycles at 95 ˚C for 15 s, and 40
cycles at 60 ˚C for 1 min. During each annealing phase, SYBR
green fluorescence was detected and recorded. The cycle threshold
(Ct) values were recorded for each of the 96 wells, and expression
levels were calculated using a standard equation for ΔΔCt. All
expression levels were normalized to that of the housekeeping gene
ribosomal protein L13 (RPL13), which did not vary significantly
between PASM and S-LAM1 cells. The relative gene expression
was examined by calculating the n-fold change in expression levels
in the LAM cells, as compared with the PASMs. The p-values were
calculated based on a Student’s t-test of the replicate ΔΔCt values
for each gene in the PASM and S-LAM1 cells, and p-values less
than 0.05 were considered as statistically significant.
Sulforhodamine B (SRB) cell viability assay. S-LAM1 cells were
plated at a density of 15,000 per well in 96-well format. The cells were
grown for 24 h, reaching a confluence of 80%. Cells were treated with
rapamycin (Sigma) at five different concentrations: 0.1 ng/ml, 1 ng/ml,
5 ng/ml, 10 ng/ml, 25 ng/ml, or control media, for 72 h. After
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Figure 1. Immunofluorescence characterization of S-LAM1 cells. Positive staining for α-smooth muscle actin (A), HMB-45 (B), podoplanin (C), and
vimentin (D).
















































































































































































































































































































treatment, 30 μl of trichloroacetic acid (TCA) solution (50% w/v in
H2O) per 100 μl medium was added to each well. The plates were
incubated at 4˚C for 1 h for TCA cell fixation. Following fixation, the
TCA solution was removed and the cell plates were washed five times
with deionized water and allowed to dry at ambient temperature. Once
the plates were completely dry, the cells were stained with SRB (0.4%
in acetic acid, 50 μl/well) for 30 min at RT and than washed four times
with 1% acetic acid in order to remove excess unbound dye. SRB was
extracted from the dry, stained cells through the addition of 150 μl of
Tris base (10 mM) and incubation for 30 min at RT. Absorbance was
read at 564 nm on a universal microplate reader ELX800 (BIO-TEK
Instruments, Inc., Winooski, VT, USA). The viability was expressed
as a percentage that of the control treated with media. Student’s t-test
was used for the statistical analysis, p-values less than 0.05 were
considered statistically significant.
Results
Phenotypic and ultrastructural characterization of the
cultured cells. We established a primary culture of S-LAM1
cells derived from the chylous effusion from a 42-year-old
patient with pulmonary, sporadic LAM. The S-LAM1 cells
were spindle-shaped. Immunofluorescence staining was
conducted to characterize the S-LAM1 cells in vitro.
Immunofluorescence staining exhibited significant αSMA
(Figure 1A) and vimentin (Figure 1D) expression, that
revealed the presence of intermediate actin and vimentin
filaments. Staining with HMB-45 (Figure 1B), which is
characteristic of melanoma cells, showed granular
immunoreactivity with this antibody in the cytoplasm of
cultured cells. Additionally, S-LAM1 cells exhibited strong-
positive membrane expression of podoplanin (D2-40) (Figure
1C), a marker of lymphatic endothelial cells. 
To further characterize the phenotype of the studied cells,
flow cytometry was performed. Immunophenotypic analysis
revealed that most cells exhibited co-expression of αSMA and
HMB-45 (65,4%), vimentin and CD9 (95,9%), CD29 and
CD90 (99,7%) and a lack of expression of CD45, CD31,
CD133, STRO1, and c-MET (Figure 2). The expression of
HMB-45, αSMA, vimentin, CD9, CD29, CD90, CD45, CD133,
c-MET was further evaluated using an Image Stream System
(flow-based imaging system). Co-expression of particular
antigens in single LAM cells are presented in Figure 3.
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Figure 4. Electron micrographs of S-LAM1 cell ultrastructure. A: Irregular surface of cell membrane due to the presence of cytoplasmic protrusions.
Nucleus (n) is large, irregular and eccentrically located. Numerous tiny mitochondria (m) and lipid granules (l) are observed in cytoplasm. B:
Cytoplasm of S-LAM1 cells contains electron-dense granules resembling immature melanosomes (arrows).
Figure 5. Real-time polymerase chain reaction (PCR) 'cell motility'
array, volcano plot. The vertical line in the middle of the plot indicates
an n-fold change in gene expression of 1. The vertical lines on the left
and on the right from the middle line indicate the desired n-fold change
in gene expression threshold, defined as 2. The horizontal line indicates
the desired threshold for the p-value of the t-test, defined as 0.05. The
dots represent 84 genes involved in cell motility. Up-regulated genes in
S-LAM1 cells are located in the upper-right square,while down-
regulated genes are located in the upper-left square.
Ultrastructural analysis revealed that the S-LAM1 cells are
covered with protrusions and microvilli, and have abnormal,
irregular nuclei with a predominance of euchromatin over
heterochromatin and containing 1-3 nucleoli. In the cytoplasm,
numerous tiny mitochondria, lysosomes, some lipid granules, and
expanded rough endoplasmic reticulum were observed, which
indicate the intense metabolism typical of tumor cells. The
presence of intermediate actin filaments and structures resembling
pre-melanosomes supports the fact that LAM cells involve both
the smooth muscle and melanoma lineages (Figure 4).
Human cell motility PCR array. To gain insight into the
ability of S-LAM1 cells to metastasize, a real-time PCR
analysis of 84 genes involved in cell motility was performed.
The volcano plot in Figure 5 shows the relative change in
gene expression between the tested samples (S-LAM1 cells)
and the control cells (PASMc). A total of 34 genes exhibited
at least a two-fold difference in the expression of all 84 cell
motility genes in this array, with 29 genes being up-regulated
and five genes being down-regulated in the LAM cultured
cells; the p-value for the t-test was less than 0.05 (Figure 6).
These genes are strictly associated with chemotaxis, adhesion,
cellular projections, and membership of the RHO family of
GTPases. The genes that were found to exhibit a more than
fivefold change in expression are presented in Table I.
Rapamycin inhibits LAM cell viability. In order to study the
effect of rapamycin on the proliferation of S-LAM1 cells, 
we employed five different doses of rapamycin: 0.1 ng/ml, 
1 ng/ml, 5 ng/ml, 10 ng/ml, 25 ng/ml, and SRB. A cell
viability assay was performed. The treatment of S-LAM1
cells with increasing doses of rapamycin resulted in a
decrease in cell proliferation at doses of 1 ng/ml and higher
(p<0.05). There were no statistically significant differences
at doses lower than this. We observed 18%, 26%, 30%, and
34% inhibition of LAM cell viability following rapamycin
treatment with doses of 1 ng/ml, 5 ng/ml, 10 ng/ml, and 25
ng/ml, respectively (Figure 7). There were no significant
differences in cell viability between untreated cells (the
control) and cells treated with the solvent control.
Discussion
LAM is a very rare interstitial lung disease. LAM cells are
characterized by their excessive proliferation and ability to
metastasize (4, 17). The phenotype of LAM cells combines
the features of smooth muscle cells, lymphatic endothelial
cells, and melanoma (18, 19). A mutation in one of the TSC1
or TSC2 genes results in the activation of mTOR kinase,
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Figure 6. Real-time polymerase chain reaction (PCR) 'cell motility'. A total of 34 out of 84 genes which entitled an at least two-fold and statistically
significant change in expression in the S-LAM1 compared to PASMc cells (p<0.05).
Figure 7. Cell viability of rapamycin-treated S-LAM1 cells. *p<0.05
versus untreated cells (control). C, Control; SC, solvent control.
which is responsible for the regulation of growth,
proliferation, and cell movement (17). The natural inhibitor
of mTOR is rapamycin (4, 16). Although LAM occurs
extremely rarely, dysregulation of the mTOR kinase pathway
is involved in the pathogenesis of various human diseases,
particularly cancer (i.e. breast cancer, lung cancer,
melanoma, glioblastoma), hence the LAM cell line may be
an interesting experimental model. The aim of our study was
to phenotypically characterize cells cultured from chylous
effusion obtained from a patient with sporadic, pulmonary
LAM. In the next step, we evaluated the expression of 84
genes involved in cell motility. The effect of treatment with
a natural inhibitor of mTOR kinase, rapamycin, on the
viability of the S-LAM1 cells was also assessed. 
The phenotypic evaluation of the S-LAM1 cell line using
immunofluorescence staining showed the expression of αSMA,
podoplanin (a marker of the lymphatic endothelium) and
vimentin, as well as immunoreactivity with HMB-45 antibody,
which reacts against an antigen present in melanocytic tumors,
such as melanomas. Immunohistochemical staining with HMB-
45 has become a useful diagnostic tool for LAM (7, 20). The
combined smooth muscle and melanocytic differentiation in
LAM was described in the study of Zhe et al. (6). The
expression of melanocytic and smooth muscle markers in LAM
cells has been extensively presented in the literature (18, 21,
22). The expression of vimentin, a type-III intermediate
filament expressed mostly in mesenchymal cells, has been
shown in proliferating spindle-shaped LAM cells in cases of
pulmonary LAM (23, 24). The lymphatic endothelial
differentiation of LAM (anti-podoplanin) cells is still
controversial. The first immunohistochemical study using the
D2-40 antibody reported no expression of podoplanin in LAM-
like cells. Immunoreactivity with D2-40 has been shown in
thin-wall lymphatic vessels accompanying LAM lesions (25).
Contrary to these results, Davis et al. showed in their recent
study positive immunohistochemical reaction of D2-40 in the
majority of LAM cells in all the cases of sporadic LAM they
investigated; there were no differences between early-stage and
late-stage cases. Additionally, the expression of other
lymphatic-specific markers, such as prospero homeobox
protein 1 (PROX1), vascular endothelial growth factor receptor
3 (VEGFR3), and lymphatic vessel endothelial receptor 1
(LYVE1), was also shown in their study of LAM cells, which
provides evidence that LAM cells in sporadic LAM may have
an additional lineage of lymphatic endothelial differentiation
(19). Our study supports these recent results. 
Phenotypic evaluation of S-LAM1 cells by flow cytometry
confirmed the expression of αSMA, HMB-45, and vimentin in
these cells. Furthermore, we showed herein the expression of
mesenchymal stem cell markers such as CD29, CD90, and
CD105 in S-LAM1 cells. The origin of LAM cells remains
unclear, but common features between migrating LAM cells
and mesenchymal stem cells and cancer stem cells have been
observed (2). It has been suggested that LAM cells may come
from normal resident pulmonary vascular smooth muscle cells
that undergo spontaneous somatic mutation, resulting in
increased proliferation (17). Yan et al. described mesenchymal
stem cell-like cells expressing the mesenchymal stem cells-
specific surface proteins CD29, CD44, CD73, CD90 and
CD105, which were derived from renal angiomyolipoma (26).
These data suggest that one possible source of LAM cells in
the lung could be the population of mesenchymal stem cells
that have undergone spontaneous mutations and have
differentiated into a migratory and proliferative phenotype. All
S-LAM1 cells assessed by flow cytometry exhibited
immunostaining with the antibody against CD9. CD9 is a cell
surface glycoprotein that belongs to the tetraspanin family and
is responsible for the modulation of adhesion, cell motility, and
migration (27). The role of CD9 in many different types of
carcinomas is variable. CD9 down-regulation correlates with
increased cell motility and tumor progression in some types of
carcinoma, such as breast, lung, and pancreatic carcinoma;
other studies, however, show CD9 to be a cancer marker
protein or an oncogene in ovarian carcinoma. Cancer such as
head and neck squamous cell carcinoma, small-cell lung cancer
and gastric cancer express higher levels of CD9 in their late
stages (27, 28). As well as CD44v6, Cai et al. identified CD9
as a marker of disseminated cells with TSC2 loss of
heterozygosity in patients with LAM (10). Although we know
that LAM cells express CD9, the role of this protein in LAM
remains unclear. S-LAM1 cells did not show immunoreactivity
with antibodies against CD45, CD31, c-MET, STRO1, or
CD133. The expression of selected antigens assessed by flow
cytometry was imaged using an Image Stream System, which
shows the co-expression of these antigens in a single cell. The
presence of intermediate actin filaments and electron-dense
structures resembling pre-melanosomes, as seen in TEM,
explains the immunoreactivity of the investigated S-LAM1
cells with antibodies characteristic of smooth muscle cell α-
SMA and melanoma HMB-45. The cytoplasmic granules in
LAM cells with electron-dense contents that show
immunoreactivity with HMB-45 are considered immature
melanosomes (stage I and II premelanosomes), and have been
previously described (5, 18). The presence of protrusions and
microvilli that cover the surface of the S-LAM1 cells reflects
the motility of these cells. The phenotype of the S-LAM1 cell
line presented in our study is consistent with the phenotypic
features and biology of LAM cells.
The S-LAM1 cell line used in this study was derived
from the chylous effusion of a patient with sporadic LAM,
and we therefore expected this population to have the ability
to move and migrate. The analysis of 84 genes involved in
cell motility mechanisms in S-LAM1 cells, and the
comparison with their expression in PASMc normal vascular
smooth muscle cells, showed at least a two-fold change in
the expression of 34 genes. Those genes that exhibited
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altered expression were related to cell growth, chemotaxis,
adhesion, RHO signaling, integrin-mediated signaling,
cellular projections, cell polarity, and proteolysis. We
identified seven genes whose expression was altered by at
least a factor of five and may be involved in LAM
pathophysiology: EZR; HGF; insulin-like growth (IGF1);
myosin, heavy chain 10, nonmuscle (MYH10); myosin light
chain kinase (MYLK); RHO family GTPase 3 (RND3), and
supervillin (SVIL) (Table I). 
Ezrin belongs to the ERM (ezrin-radixin-moesin)
cytoskeleton-associated protein family and plays a crucial
role in cell adhesion to the intracellular matrix, cell–cell
interactions, receptor tyrosine-kinase signaling, RHO-
GTPase signaling, and interactions with the protein kinase B
(AKT)-mediated cellular apoptotic mechanisms; it is
therefore thought to be involved in the cellular complexes
and signaling pathways required for effective metastasis (29).
It has been shown that ezrin plays an important role in the
tumorigenicity and metastasis of lung cancer cells, and its
silencing results in a reduction in cell migration and
invasion; it also sensitized cancer cells to antitumor drugs
(30). In pancreatic cancer cells, ezrin, by enhancing the
formation of cell protrusions and cell microvilli and thus
inducing ERK1/2 activation, has been shown to promote
invasion and metastasis (31). Increased levels of ezrin in
LAM cells, compared to normal vascular smooth muscle
cells, may be associated with these cells’ ability to migrate
and metastasize. Wan et al. found a link between ezrin and
mTOR signaling. The suppression of ezrin protein or the
disruption of its function reduced lung metastasis in a mouse
model, and also inhibited AKT phosphorylation and
decreased the expression and phosphorylation of ribosomal
protein S6 kinase (S6K1) and eukaryotic initiation factor 4E-
binding protein 1 (4E-BP1), which are downstream targets
of the mTOR pathway, in the K2M2 murine model of
osteosarcoma (32). The role of ezrin in LAM cell metastatic
behavior and its possible linkage with mTOR dysregulation
in LAM is worth further evaluation. 
Cell spreading is an early step in the complex cell motility
process. Supervillin has been identified as a membrane-
associated scaffolding protein that binds to MYH9, MYH10,
MYLK, and actin filaments, and through this interaction
inhibits cell spreading (33). It has been shown that a
population of supervillin-transfected COS7 cells spreads less
well than non-transfected cells on fibronectin and that the
silencing of supervillin in A549 cells results in an increased
rate of cell spreading (33). Myosin IIA and (especially)
myosin IIB play an active role in promoting cell spreading
(34), and thus cancer cell invasiveness (35). Myosin light-
chain kinase, a calcium/calmodulin dependent enzyme,
phosphorylates myosin regulatory light chains to facilitate
myosin interaction with actin filaments, producing
contractile activity. Inhibition of this kinase results in
reduced cell spreading (34). The pattern of highly increased
expression of MYH9, MYH10, and MYLK, accompanied by
much decreased SVIL expression in S-LAM1 cells, as
presented in our study, may be responsible for the promotion
of LAM cell spreading, and thus of migration and metastasis.
RND3 is a protein involved in organization of the actin
cytoskeleton and cell-cycle regulation, which has been
described as a protein capable of inhibiting cell-cycle
progression and inducing apoptosis in glioblastoma and
prostate cancer cells (36). It has been shown that
phosphorylation of 4E-BP1 is strongly suppressed in 3T3
RHOE-expressing cells and that RHOE may inhibit the 4E-
BP1/eIF4E axis. Villalonga et al. suggest that it would be
interesting to investigate whether there is a correlation
between RHOE and eIF4E expression in tumors, and at the
same time to assess the impact of RHOE as a modulator of
the oncogenic function of eIF4E (37). RND3 has been found
to be up-regulated in subependymal giant cell astrocytomas,
which are rare brain tumors associated with TSC (36).
Similarly, we found RND3 gene expression to be up-
regulated in S-LAM1 cells compared to the control. The role
of RND3 in LAM and in the mTOR pathway remains
unclear, and needs to be further investigated. 
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Table I. Real-time PCR 'cell motility' array: genes which showed at least a five-fold statistically significant change in expression in the S-LAM1
cells compared to PASMc (p<0.05), and their role in cell motility mechanisms.
Gene symbol Name Up/down-regulation Role in cell motility
multiplier
EZR Ezrin 12.01 Cell–cell adhesion, cell polarity, cellular projections 
(filopodia, membrane blebs, invasive projections, membrane ruffles)
HGF Hepatocyte growth factor 26.61 Growth factor, proteolysis
IGF-1 Insulin-like growth factor 1 −5.85 Growth factor
MYH10 Myosin, heavy chain 10, nonmuscle 5.18 Chemotaxis, cellular projections (stress fibers, membrane blebs)
MYLK Myosin light chain kinase 26.28 RHO signaling, cellular projections (membrane blebs)
RND3 Rho family GTPase 3 7.01 RHO signaling, cellular projections (membrane blebs)
SVIL Supervillin −13.40 Cellular projections (filopodia, lamellipodia, invasive projections)
Among growth factors, expression of HGF, which has
been found to induce cancer cell motility (38, 39), increased
greatly in S-LAM1 cells as compared to the PASMc normal
vascular smooth muscle cells.
Rapamycin is a natural inhibitor of the mTOR signaling
pathway and controls translation and cell proliferation.
Rapamycin binds to the 12 kDa FK506 binding protein
(FKBP12) cytosolic protein and inactivates mTOR kinase.
Treatment with rapamycin results in a reduction in tumor volume
and improved lung function in patients with LAM (15, 16).
Treatment of S-LAM1 cells with increasing doses of rapamycin
results in a decrease in cell proliferation at doses of 1 ng/ml and
higher. It was reported by Lesma et al. that the treatment of
TSC2−/− ASM cells, derived from an angiomyolipoma of a
patients with TSC, with rapamycin at a dose of 1 ng/ml added at
plating time was able to inhibit mTOR and the cell proliferation
rate; however, the same dose added 3 h after plating did not
affect cell proliferation (40). Interestingly, the higher doses of
rapamycin (5 ng/ml, 10 ng/ml, 25 ng/ml) only slightly slowed
S-LAM1 cell proliferation compared to rapamycin at a dose of 1
ng/ml. In the previously mentioned study, 10 ng/ml and 20 ng/ml
concentrations of rapamycin, added 3 h after plating, also only
slightly reduced TSC2−/− ASM cell proliferation. The influence
of higher concentrations of rapamycin added at plating time on
TSC2−/− ASM cell proliferation has not been shown (40). The
hypothesis that rapamycin only partially inhibits cell growth,
proliferation, and disease progression has been previously
presented (41). It is possible that 1 ng/ml of rapamycin used in
vitro is able to partially inhibit the proliferation of LAM cells,
but the highly increased doses of rapamycin do not change this
effect significantly. Using another agent that would synergize
with rapamycin might perhaps inhibit further LAM cell
proliferation, should be considered in the research into and
treatment of LAM.
In summary, we developed a cell line derived from the
chylous effusion from a patient with sporadic LAM. The
phenotype of the cell line is consistent with the biology of LAM
cells. S-LAM1 presents combined smooth muscle, melanocytic,
and lymphatic lineage as well as the expression of mesenchymal
markers, and can be considered a useful in vitro model of LAM.
The particular pattern of gene expression, including the high
expression of EZR, MYH10, and MYLK, and the much
decreased expression of SVIL when compared to controls,
indicate a high rate of motility activity, and especially of cell
spreading. Rapamycin significantly but partially inhibits LAM
cell proliferation in vitro, and should perhaps be considered in
the future for use in combination with other agents. 
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